[10-Q] IGC Pharma, Inc. Quarterly Earnings Report
IGC Pharma filed its quarterly report for the period ended September 30, 2025. The company reported revenue of $191 thousand for the quarter and a net loss of $1.821 million. R&D expenses rose to $1.588 million as the Phase 2 trial of IGC‑AD1 advanced past the 50% enrollment mark.
Other income was $1.078 million, reflecting a gain from the sale of assets at the Vancouver, Washington facility. The transaction delivered approximately $2.7 million in consideration versus about $1.5 million of carrying value, and included preferential supply rights and a contingent 10% interest on a potential future sale by the buyer.
Cash and cash equivalents were $1.105 million at September 30, 2025, with working capital of $490 thousand. The company amended and extended its $12 million credit facility, reducing the annual facility fee and setting interest at the certificate of deposit rate plus a 1.2% margin. For the six months, revenue was $519 thousand and net cash used in operations was $3.497 million. Common shares outstanding were 91,959,112 as of September 30, 2025.
- None.
- None.
Insights
R&D spend increased as a Phase 2 trial progressed; liquidity supported by a
IGC Pharma emphasized clinical progress, with Phase 2 enrollment surpassing 50%, and R&D at
Liquidity at period-end included cash of
Key near-term variables are trial execution and cost discipline. Subsequent filings may detail clinical milestones and any drawdown activity; actual capital needs will depend on trial pace and operating expenses.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
For the quarterly period ended
Commission
file number:
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
| (Address of principal executive offices) | (Zip Code) |
(
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. ☑
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). ☑
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ | |
| Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes
 |
| September 30, 2025, Form 10-Q |
IGC PHARMA, INC.
FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2025
Table of Contents
| Page | ||
| PART I. FINANCIAL INFORMATION | ||
| Item 1. | Financial Statements | 4 |
| Condensed Consolidated Balance Sheets | 4 | |
| Condensed Consolidated Statements of Operations and Comprehensive Loss | 5 | |
| Condensed Consolidated Statements of Changes in Shareholder’s Equity | 6 | |
| Condensed Consolidated Statements of Cash Flows | 7 | |
| Notes to Condensed Consolidated Financial Statements | 8 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 21 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 28 |
| Item 4. | Controls and Procedures | 28 |
| PART II. OTHER INFORMATION | ||
| Item 1. | Legal Proceedings | 29 |
| Item 1A. | Risk Factors | 29 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 30 |
| Item 3. | Defaults Upon Senior Securities | 30 |
| Item 4. | Mine Safety Disclosures | 30 |
| Item 5. | Other Information | 30 |
| Item 6. | Exhibits | 31 |
| SIGNATURES | 32 | |
| |
| September 30, 2025, Form 10-Q |
Table of Contents
FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q and the documents incorporated herein by reference contain “forward-looking statements.” Additionally, we, or our representatives, may, from time to time, make other written or verbal forward-looking statements and discuss plans, expectations, and objectives regarding our business, financial condition, and results of operations. Without limiting the foregoing, statements that are in the future tense, and all statements accompanied by terms such as “believe,” “hope,” “potential,” “project,” “expect,” “trend,” “estimate,” “forecast,” “assume,” “intend,” “plan,” “target,” “anticipate,” “outlook, “preliminary,” “will likely result,” “will continue,” and variations of them and similar terms are intended to be “forward-looking statements” as defined by federal securities laws. Such statements are based on currently available information, which management has assessed but which is dynamic and subject to rapid change due to risks and uncertainties that affect our business.
For the next several years, we believe our success is highly correlated with the outcome of our clinical trials and, secondarily, with the sale of our products and services. The Company may not be able to complete human trials on our investigational drug candidates, or, once conducted, the results of human trials may not be favorable or as anticipated or may reflect a lack of efficacy in humans or animals. Precautions, including social distancing and travel restrictions, among others, could lead to delays or expenses greater than anticipated or projected. Failure or delay with respect to any of the above factors could have a material adverse effect on our business, future results of operations, stock price, and financial condition.
Our projections and investments anticipate certain regulatory changes and stable pricing, which may not hold out over the next several years. We may not be able to protect our intellectual property adequately or receive patents. We may not receive regulatory approval for our products or trials. The patent applications we have licensed may not be granted by the United States Patent and Trademark Office (“USPTO”), even if the Company is in full compliance with USPTO requirements. We may not have adequate resources, including financial resources, to successfully conduct all requisite clinical trials, to bring a product based on the above-referenced patented formulations to market, or to pay applicable maintenance fees over time. We may not be able to successfully commercialize our products even if they are successful and receive regulatory approval, including, but not limited to, based on the Food and Drug Administration’s (“FDA”) current position on hemp and hemp-based products. Failure or delay with respect to any of the factors above could have a material adverse effect on our business, future results of operations, stock price, and financial condition.
This document also contains statements that are not approved by the FDA, including but not limited to the statements on hemp and hemp extracts and their potential efficacy on humans and animals. While these statements and claims are intended to be in compliance with federal and state laws, we cannot guarantee such compliance.
We caution you not to place undue reliance on forward-looking statements, which are based upon assumptions, expectations, plans, and projections subject to risks and uncertainties, including those, if any, identified in the “Risk Factors” set forth in this report or in our annual report on Form 10-K for the fiscal year ended March 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on June 27, 2025 and other documents that we subsequently file with the SEC that update, supplement or supersede such information, which may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements speak only as of the date when they are made. Except as required by federal securities law, we do not undertake any obligation to update forward-looking statements to reflect events, circumstances, changes in expectations, or the occurrence of unanticipated events after the date of those statements.
| |
| September 30, 2025, Form 10-Q |
3
Table of Contents
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
IGC Pharma, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
(Unaudited)
| September 30, 2025 ($) | March 31, 2025 ($) | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | ||||||||
| Accounts receivable, net | ||||||||
| Inventory | ||||||||
| Short-term investment | ||||||||
| Asset held for sale | ||||||||
| Deposits and advances | ||||||||
| Total current assets | ||||||||
| Non-current assets: | ||||||||
| Intangible assets, net | ||||||||
| Property, plant, and equipment, net | ||||||||
| Claims and advances | ||||||||
| Operating lease asset | ||||||||
| Total non-current assets | ||||||||
| Total assets | ||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | ||||||||
| Accrued liabilities and others | ||||||||
| Total current liabilities | ||||||||
| Non-current liabilities: | ||||||||
| Long-term loans | ||||||||
| Other liabilities | ||||||||
| Operating lease liability | ||||||||
| Total non-current liabilities | ||||||||
| Total liabilities | ||||||||
| Commitments and Contingencies – See Note 12 | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $ | ||||||||
| Common stock and additional paid-in capital, $ | ||||||||
| Accumulated other comprehensive loss | ( | ) | ( | ) | ||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ equity | ||||||||
| Total liabilities and stockholders’ equity | ||||||||
The accompanying notes should be read in connection with these Condensed Consolidated Financial Statements.
| |
| September 30, 2025, Form 10-Q |
4
Table of Contents
IGC Pharma, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except loss per share and share data)
(Unaudited)
| Three months ended September 30, | Six months ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| ($) | ($) | ($) | ($) | |||||||||||||
| Revenue | ||||||||||||||||
| Cost of revenue | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Gross profit | ||||||||||||||||
| Selling, general, and administrative expenses | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Research and development expenses | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Operating loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income, net | ||||||||||||||||
| Loss before income taxes | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Income tax expense | ||||||||||||||||
| Net loss attributable to common stockholders | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Foreign currency translation adjustments | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Comprehensive loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net loss per share attributable to common stockholders: | ||||||||||||||||
| Basic and diluted | $ | ( | ) | ( | ) | ( | ) | ( | ) | |||||||
| Weighted-average number of shares used in computing loss per share amounts: | ||||||||||||||||
The accompanying notes should be read in connection with these Condensed Consolidated Financial Statements.
| |
| September 30, 2025, Form 10-Q |
5
Table of Contents
IGC Pharma, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands)
(Unaudited)
| Three months ended September 30, 2024 | Number of Common Shares | Common Stock and Additional Paid in Capital ($) | Accumulated Deficit ($) | Accumulated Other Comprehensive Loss ($) | Total Stockholders’ Equity ($) | |||||||||||||||
| Balances as of June 30, 2024 | ( | ) | ( | ) | ||||||||||||||||
| Common stock-based compensation & expenses, net | - | - | - | |||||||||||||||||
| Share money received but not allotted | - | - | - | |||||||||||||||||
| Issuance of common stock through offering (net of expenses) | - | - | ||||||||||||||||||
| Cancellation/forfeiture of shares | - | - | - | - | ||||||||||||||||
| Net loss | - | - | ( | ) | - | ( | ) | |||||||||||||
| Foreign currency translation adjustments | - | - | - | ( | ) | ( | ) | |||||||||||||
| Reclassification due to the liquidation of Subsidiaries | - | - | - | - | ||||||||||||||||
| Balances as of September 30, 2024 | ( | ) | ( | ) | ||||||||||||||||
| Three months ended September 30, 2025 | ||||||||||||||||||||
| Balances as of June 30, 2025 | ( | ) | ( | ) | ||||||||||||||||
| Common stock-based compensation & expenses, net | - | - | - | |||||||||||||||||
| Share money received but not allotted | - | - | - | - | - | |||||||||||||||
| Issuance of common stock through offering (net of expenses) | - | - | ||||||||||||||||||
| Cancellation/forfeiture of shares | - | - | - | - | - | |||||||||||||||
| Net loss | - | - | ( | ) | - | ( | ) | |||||||||||||
| Foreign currency translation adjustments | - | - | - | ( | ) | ( | ) | |||||||||||||
| Reclassification due to the liquidation of Subsidiaries | - | - | ( | ) | ||||||||||||||||
| Balances as of September 30, 2025 | ( | ) | ( | ) | ||||||||||||||||
| Six months ended September 30, 2024 | Number of Common Shares | Common Stock and Additional Paid in Capital ($) | Accumulated Deficit ($) | Accumulated Other Comprehensive Loss ($) | Total Stockholders’ Equity ($) | |||||||||||||||
| Balances as of March 31, 2024 | ( | ) | ( | ) | ||||||||||||||||
| Common stock-based compensation & expenses, net | - | - | - | |||||||||||||||||
| Share money received but not allotted | - | - | - | |||||||||||||||||
| Issuance of common stock through offering (net of expenses) | - | - | ||||||||||||||||||
| Cancellation/forfeiture of shares | - | - | - | - | - | |||||||||||||||
| Net loss | - | - | ( | ) | - | ( | ) | |||||||||||||
| Foreign currency translation adjustments | - | - | - | ( | ) | ( | ) | |||||||||||||
| Reclassification due to the liquidation of Subsidiaries | - | - | - | - | ||||||||||||||||
| Balances as of September 30, 2024 | ( | ) | ( | ) | ||||||||||||||||
| Six months ended September 30, 2025 | ||||||||||||||||||||
| Balances as of March 31, 2025 | ( | ) | ( | ) | ||||||||||||||||
| Common stock-based compensation & expenses, net | - | - | - | |||||||||||||||||
| Share money received but not allotted | - | - | - | - | - | |||||||||||||||
| Issuance of common stock through offering (net of expenses) | - | - | ||||||||||||||||||
| Cancellation/forfeiture of shares | - | - | - | - | - | |||||||||||||||
| Net loss | - | - | ( | ) | - | ( | ) | |||||||||||||
| Foreign currency translation adjustments | - | - | - | ( | ) | ( | ) | |||||||||||||
| Reclassification due to liquidation of Subsidiaries | - | - | ( | ) | ||||||||||||||||
| Balances as of September 30, 2025 | ( | ) | ( | ) | ||||||||||||||||
The accompanying notes should be read in connection with these Condensed Consolidated Financial Statements.
| |
| September 30, 2025, Form 10-Q |
6
Table of Contents
IGC Pharma, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)
| Six months Ended September 30, | ||||||||
| 2025 ($) | 2024 ($) | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | ( | ) | ( | ) | ||||
| Adjustment to reconcile net loss to net cash: | ||||||||
| Depreciation and amortization | ||||||||
| Common stock-based compensation and expenses, net | ||||||||
| Other non-cash items | ( | ) | ( | ) | ||||
| Changes in: | ||||||||
| Accounts receivables, net | ( | ) | ( | ) | ||||
| Inventory | ||||||||
| Deposits and advances | ( | ) | ||||||
| Claims and advances | ||||||||
| Accounts payable | ( | ) | ( | ) | ||||
| Accrued and other liabilities | ( | ) | ||||||
| Operating lease asset | ||||||||
| Operating lease liability | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flow from investing activities: | ||||||||
| Purchase of property, plant, and equipment | ( | ) | ( | ) | ||||
| Sale of property, plant, and equipment | ||||||||
| Investment in short-term investment | ( | ) | ||||||
| Acquisition and development of intangible assets | ( | ) | ( | ) | ||||
| Net cash from (used) in investing activities | ( | ) | ||||||
| Cash flows from financing activities: | ||||||||
| Net proceeds from the issuance of common stock | ||||||||
| Repayment of long-term loan | ( | ) | ( | ) | ||||
| Net cash provided by financing activities | ||||||||
| Effects of exchange rate changes on cash and cash equivalents | ( | ) | ||||||
| Net increase in cash and cash equivalents | ||||||||
| Cash and cash equivalents at the beginning of the period | ||||||||
| Cash and cash equivalents at the end of the period | ||||||||
| Supplementary information: | ||||||||
| Cash used in an investing activity for acquiring a Favorable Contract against the Disposition of Assets (Note – 7) | ( | ) | ||||||
| Interest paid | ( | ) | ( | ) | ||||
| Other non-cash items: | ||||||||
| Profit on the Disposition of Assets, (Note -7) | ( | ) | ||||||
| Profit on sales of PPE | ( | ) | ( | ) | ||||
The accompanying notes should be read in connection with these Condensed Consolidated Financial Statements.
| |
| September 30, 2025, Form 10-Q |
7
Table of Contents
IGC Pharma, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS AND SIX MONTHS ENDED SEPTEMBER 30, 2025
(in thousands, except for share data and loss per share, unaudited)
Unless the context requires otherwise, all references in this report to “IGC,” “IGC Pharma,” “the Company,” “we,” “our,” and “us” refer to IGC Pharma, Inc., together with our subsidiaries and beneficially owned subsidiary. Our public filings with the Securities and Exchange Commission, the “SEC,” are available on www.sec.gov. The information contained on our various websites, including www.igcpharma.com, is not incorporated by reference in this report, and you should not consider such information to be a part of this report. We exclude our investments and minority non-controlling interests, and any information provided by them is not incorporated by reference in this report, and you should not consider such information to be a part of this report.
NOTE 1 – BUSINESS DESCRIPTION
Overview
IGC
Pharma Inc. is a clinical-stage pharmaceutical company attempting to utilize Artificial Intelligence (AI) technologies to develop innovative
therapies for Alzheimer’s Disease (AD), related neurodegenerative disorders, and metabolic conditions. The Company’s lead
therapeutic candidate, IGC-AD1, is currently in Phase 2 clinical development targeting agitation in Alzheimer’s dementia—a
prevalent and debilitating behavioral symptom. During the quarter ended September 30, 2025, IGC Pharma successfully enrolled more than
In parallel, IGC Pharma is accelerating the integration of its proprietary AI platform in an effort to enhance drug discovery, optimize clinical trial design, and identify novel therapeutic targets. The Company’s AI models attempt to leverage multimodal data—from clinical biomarkers to behavioral patterns—in an effort to predict treatment response, enable early disease detection, and support the creation of precision-based therapies in Alzheimer’s and other neurological diseases, although there can be no assurance thereof. We believe this AI-driven infrastructure not only strengthens internal research productivity but also positions IGC Pharma as an emerging player in the convergence of pharmaceuticals and intelligent data science, although there can be no assurance thereof.
IGC Pharma remains committed to advancing its clinical and AI-enabled programs to address major unmet medical needs in Alzheimer’s and related disorders, while creating enduring value for patients, caregivers, and shareholders.
Business Organization
As of September 30, 2025, the Company had the following operating subsidiaries: HH Processors, LLC, IGC Pharma IP, LLC, IGC Pharma, LLC, SAN Holdings, LLC, Hamsa Biopharma India Pvt. Ltd., and Colombia-based beneficially owned subsidiary IGC Pharma SAS. During the quarter ended September 30, 2025, the Company shut down a few of its non-operating subsidiaries, which had a negligible impact on the financial statements. The Company’s fiscal year is the 52- or 53-week period that ends on March 31. The Company’s principal office is in Maryland, established in 2005. Additionally, the Company has offices in Colombia, South America, and India. The Company’s filings are available on www.sec.gov.
| |
| September 30, 2025, Form 10-Q |
8
Table of Contents
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of presentation
The accompanying condensed consolidated balance sheet as of September 30, 2025, and March 31, 2025, condensed consolidated statements of operations for the three months and six months ended September 30, 2025, and 2024, and condensed consolidated statements of cash flows for the six months ended September 30, 2025, and 2024, are unaudited. The consolidated balance sheet as of March 31, 2024, has been derived from audited financial statements, and the accompanying as of September 30, 2025 unaudited condensed consolidated financial statements (interim statements) of the Company have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) as determined by the Financial Accounting Standards Board (the FASB) within its Accounting Standards Codification (ASC) and under the rules and regulations of the SEC.
Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments and disclosures necessary for a fair presentation of these interim statements have been included. The results reported in these interim statements are not necessarily indicative of the results that may be reported for the entire year. These interim statements should be read in conjunction with the Company’s audited consolidated financial statements for the fiscal year ended March 31, 2025 (Fiscal 2025) contained in the Company’s Form 10-K for Fiscal 2025, filed with the SEC on June 27, 2025, specifically in Note 2 to the consolidated financial statements.
Principles of consolidation
The
interim statements include the consolidated accounts of the Company and its subsidiaries. Intercompany accounts and transactions have
been eliminated. In the opinion of the Company’s management, the interim statements reflect all adjustments, which are normal and
recurring in nature, necessary for fair financial statement presentation. Transactions between the Company and its subsidiaries are eliminated
in the consolidated financial statements. Upon liquidation of foreign subsidiaries, the cumulative translation adjustment of $
Presentation and functional currencies
IGC operates in the U.S., India, and Colombia, and a substantial portion of the Company’s financials are denominated in the Indian Rupee (INR), or the Colombian Peso (COP). As a result, changes in the relative values of the U.S. Dollar (USD), the INR, or the COP affect our financial statements.
The accompanying financial statements are reported in USD. The INR and COP are the functional currencies for certain subsidiaries of the Company. The translation of the functional currencies into USD is performed for assets and liabilities using the exchange rates in effect at the balance sheet date and for revenues and expenses using average exchange rates prevailing during the reporting periods. Adjustments resulting from the translation of functional currency financial statements to the reporting currency are accumulated and reported as other comprehensive income/(loss), a separate component of shareholders’ equity. Transactions in currencies other than the functional currency during the year are converted into the functional currency at the applicable rates of exchange prevailing when the transactions occurred. Transaction gains and losses are recognized in the consolidated statements of operations.
Going Concern
The Company assesses and determines its ability to continue as a going concern in accordance with the provisions of ASC Subtopic 205-40, “Presentation of Financial Statements—Going Concern”, which requires the Company to evaluate whether there are conditions or events that raise substantial doubt about its ability to continue as a going concern.
The
Company is currently in a clinical trial stage and, thus, has not yet achieved profitability. The Company expects to continue to incur
significant operating and net losses and negative cash flows from operations in the near future. On June 24, 2025, the Company entered
into an amendment to extend its existing Credit Agreement of $
Agreement remains unchanged.
The
Company estimates that its current cash and cash equivalents balance, with the working capital and investments, and with an available
overdraft facility of $
| |
| September 30, 2025, Form 10-Q |
9
Table of Contents
Accounts receivable
We
make estimates of the collectability of our accounts receivable by analyzing historical payment patterns, customer concentrations, customer
creditworthiness, and current economic trends. If the financial condition of a customer deteriorates, additional allowances may be required.
We had $
Software Development Costs
The Company is developing two proprietary software platforms intended to be commercialized: -
| 1. | A clinical data management platform designed for the collection, analysis, and real-time monitoring of clinical trial data; and |
| 2. | MINT- AD - AI-driven diagnostic and treatment personalization platform aimed at assisting in the early detection of Alzheimer’s disease and providing data-informed therapeutic suggestions. |
In accordance with ASC 985-20, Software to Be Sold, Leased, or Marketed, the Company capitalizes development costs incurred after technological feasibility has been established and before the software is available for general release. Costs incurred during the research, planning, or preliminary design phase are expensed as incurred.
Capitalized
costs include direct labor, third-party development services, cloud computing infrastructure directly related to model development and
deployment, and associated overhead. These costs are amortized on a straight-line basis over their estimated useful lives, typically
As
of quarter ended September 30, 2025, the Company capitalized approximately $
Loss per share
The
computation of basic loss per share for the six months ended September 30, 2025, excludes potentially dilutive securities of approximately
The
weighted average number of shares outstanding for the six months ended September 30, 2025, and 2024, used for the computation of basic
earnings per share (EPS) is
Cybersecurity
We have a cybersecurity policy in place and have taken cybersecurity measures to safeguard against hackers, however, there can be no assurance thereof. During the six months ended September 30, 2025, there were no impactful breaches in cybersecurity.
Revenue Recognition
The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers (ASC 606). The core principle of this standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.
ASC 606 prescribes a 5-step process to achieve its core principle. The Company recognizes revenue from trading, rental, or product sales as follows:
| I. | Identify the contract with the customer. |
| II. | Identify the contractual performance obligations. |
| III. | Determine the amount of consideration/price for the transaction. |
| IV. | Allocate the determined amount of consideration/price to the performance obligations. |
| V. | Recognize revenue when or as the performing party satisfies performance obligations. |
The consideration/price for the transaction (performance obligation(s)) is determined as per the agreement or invoice (contract) for the services and products in the Life Sciences segment.
In the Life Sciences segment, the revenue from the wellness and lifestyle business is recognized once goods have been sold to the customer and the performance obligation has been completed. In retail sales, we offer consumer products through our online stores. Revenue is recognized when control of the goods is transferred to the customer. This generally occurs upon our delivery to a third-party carrier or to the customer directly. Revenue from white label services is recognized when the performance obligation has been completed and the output material has been transferred to the customer.
| |
| September 30, 2025, Form 10-Q |
10
Table of Contents
Net sales disaggregated by significant products and services for the three months and six months ended September 30, 2025, and 2024 are as follows:
| (in thousands) | ||||||||||||||||
| Three months ended September 30, 2025 ($) | Three months ended September 30, 2024 ($) | Six months ended September 30, 2025 ($) | Six months ended September 30, 2024 ($) | |||||||||||||
| Life Sciences segment | ||||||||||||||||
| Wellness and lifestyle (1) | ||||||||||||||||
| White labeling services (2) | ||||||||||||||||
| Total | ||||||||||||||||
| (1) |
| (2) |
Recently issued accounting pronouncements
Changes to U.S. GAAP are established by the FASB in the form of accounting standards updates (ASUs) to the FASB’s ASC. The Company considers the applicability and impact of all ASUs. Newly issued ASUs not listed are expected to have no impact on the Company’s consolidated financial position and results of operations, because either the ASU is not applicable, or the impact is expected to be immaterial.
ASU 2023-08, Intangibles—Goodwill and Other—Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets
In December 2023, the Financial Accounting Standards Board (FASB) issued ASU 2023-08, which requires certain crypto assets to be measured at fair value with changes recognized in net income each reporting period. The amendments also require separate presentation of crypto assets measured at fair value and provide for additional disclosure requirements, including a roll-forward of activity, cost basis, and any restrictions. The standard is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years, with early adoption permitted.
The Company’s fiscal year beginning April 1, 2025, is subject to the provisions of ASU 2023-08. Although, the Company did not hold any crypto assets directly, the Company adopted ASU 2023-08 in the first quarter of fiscal 2026 and will apply its provisions to any direct holdings of in-scope crypto assets. The Company does not expect the adoption to have a material impact on its consolidated financial statements at the date of adoption, but the presentation of any crypto asset holdings will be subject to the measurement and disclosure requirements of the new standard.
During
the six months ended September 30, 2025, the Company invested approximately $
NOTE 3 – INVENTORY
| (in thousands) | ||||||||
| As of September 30, 2025 ($) | As of March 31, 2025 ($) | |||||||
| Raw materials | ||||||||
| Finished goods | ||||||||
| Total | ||||||||
During the six months ended
September 30, 2025, and 2024, the Company wrote off approximately $
We
capitalize inventory costs related to our investigational drug, provided that management determines there is a potential alternative
use for the inventory in future research and development projects or other purposes. As of September 30, 2025, and March 31, 2025, our
consolidated balance sheet reported approximately $
| |
| September 30, 2025, Form 10-Q |
11
Table of Contents
NOTE 4 – DEPOSITS AND ADVANCES
| (in thousands) | ||||||||
| As of September 30, 2025 ($) | As of March 31, 2025 ($) | |||||||
| Advances to suppliers and consultants | ||||||||
| Other receivables and deposits | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total | ||||||||
The
Advances to suppliers and consultants primarily relate to advances to vendors. Prepaid expenses and other current assets include approximately
$
NOTE 5 – INTANGIBLE ASSETS
| (in thousands) | ||||||||||||||||||||||||
| September 30, 2025 ($) | March 31, 2025 ($) | |||||||||||||||||||||||
| Intangible Assets | Gross Amount | Accumulated Amortization | Net Amount | Gross Amount | Accumulated Amortization | Net Amount | ||||||||||||||||||
| Amortized Assets | ||||||||||||||||||||||||
| Patents | ( | ) | ( | ) | ||||||||||||||||||||
| Other intangibles | ( | ) | ( | ) | ||||||||||||||||||||
| Total amortized intangible assets | ( | ) | ( | ) | ||||||||||||||||||||
| Unamortized Assets | ||||||||||||||||||||||||
| Favorable Contract | ||||||||||||||||||||||||
| Software development cost | ||||||||||||||||||||||||
| Patents | ||||||||||||||||||||||||
| Other intangibles | ||||||||||||||||||||||||
| Total unamortized intangible assets | ||||||||||||||||||||||||
| Total Intangible Assets | ( | ) | ( | ) | ||||||||||||||||||||
The gross amount of intangible assets includes the cost of acquiring patent rights, supporting data, and the expense associated with filing various patent applications in different countries, along with granted patents. It also includes acquisition costs related to domains and licenses.
The
amortization of patents and patent rights with finite life is up to
During
the six months ended September 30, 2025, the Company recognized approximately $
The Company regularly reviews its intangible assets to determine if any intangible asset is other-than-temporarily impaired, which would require the Company to record an impairment charge in the period, and concluded that, as of September 30, 2025, there was no impairment.
| Estimated annual amortization expense | (in thousands) ($) | |||
| For the year ended 2027 | ||||
| For the year ended 2028 | ||||
| For the year ended 2029 | ||||
| For the year ended 2030 | ||||
| For the year ended 2031 | ||||
| |
| September 30, 2025, Form 10-Q |
12
Table of Contents
NOTE 6 – PROPERTY, PLANT, AND EQUIPMENT
| (in thousands, except useful life) | ||||||||||||
| Useful Life (years) | As of September 30, 2025 ($) | As of March 31, 2025 ($) | ||||||||||
| Buildings and facilities | ||||||||||||
| Plant and machinery | ||||||||||||
| Computer equipment | ||||||||||||
| Office equipment | ||||||||||||
| Furniture and fixtures | ||||||||||||
| Vehicles | ||||||||||||
| Total gross value | ||||||||||||
| Less: Accumulated depreciation | ( | ) | ( | ) | ||||||||
| Total property, plant, and equipment, net | ||||||||||||
The depreciation expense in
the three months ended September 30, 2025, and 2024 amounted to approximately $
Assets Held For Sale
During
the six months ended September 30, 2025, the Company has sold off the Nagpur land to buyers for a net value of approximately $
NOTE 7 – DISPOSITION OF ASSETS
On September 29, 2025, Holi Hemp LLC (HH Processors), a wholly owned subsidiary of the Company, entered into a Sale of Assets and Manufacturing Agreement (the “Favorable Contract”) with Wellness Essentials Northwest LLC (the Buyer) to sell certain equipment, inventory, and related operating assets of its Vancouver, Washington facility. The Company filed a Current Report on Form 8-K under Item 1.01 reporting the entrance into the Favorable Contract, subject to the satisfaction of certain closing conditions.
Under the Sale Agreement,
the Buyer assumed certain employees and lease obligations. The Company retains (i) preferential supply rights for specific formulations
produced by the Buyer and (ii) a contingent right to receive
The aggregate fair value of
consideration received for the assets sold was approximately $
In addition, the Company
spent approximately $
After
these adjustments, the net effect of the transaction was a nominal gain of approximately $
| |
| September 30, 2025, Form 10-Q |
13
Table of Contents
NOTE 8 – CLAIMS AND ADVANCES
| (in thousands) | ||||||||
| As of September 30, 2025 ($) | As of March 31, 2025 ($) | |||||||
| Claims receivable (1) | ||||||||
| Non-current deposits | ||||||||
| Total | ||||||||
| (1) |
NOTE 9 – LEFT BLANK INTENTIONALLY
NOTE 10 – ACCRUED AND OTHER LIABILITIES
| (in thousands) | ||||||||
| As of September 30, 2025 ($) | As of March 31, 2025 ($) | |||||||
| Compensation and other contributions | ||||||||
| Provision for expenses | ||||||||
| Short-term lease liabilities | ||||||||
| Other current liabilities | ||||||||
| Total | ||||||||
Compensation
and other contribution-related liabilities consist of accrued salaries and bonuses to employees. In addition, the provision for expenses
includes provision for legal, professional, and marketing expenses. Other current liability also includes statutory payables of approximately
$
NOTE 11 – LOANS AND OTHER LIABILITIES
Loan as of September 30, 2025:
On
June 11, 2020, the Company received an Economic Injury Disaster Loan (EIDL) for approximately $
| |
| September 30, 2025, Form 10-Q |
14
Table of Contents
On June 30, 2023, (the Effective Date), the Company entered into a Master
Loan and Security Agreement along with the General Banking Facility Letter (collectively called the Credit Agreement) with O-Bank, CO.,
LTD., a banking corporation incorporated under the laws of Taiwan, as administrative agent and lender (the Lender) pursuant to which
the Borrower may borrow up to USD$
On July 29, 2024, the Company entered into an amendment to extend the Credit Agreement with the Lender effective July 8, 2024.
On June 24, 2025, the Company
entered into an amendment to the Credit Agreement. The amendment extends the term of the Credit Agreement, which was set to expire, under
the same terms and conditions as previously disclosed on the Company’s Current Report on Form 8-K filed with the Securities Exchange
Commission on August 2, 2024, with the exception of i) a reduction in the facility fees from $
Other Liability:
| (in thousands) | ||||||||
| As of | ||||||||
| September 30, 2025 ($) |
March 31, 2025 ($) |
|||||||
| Statutory reserve | ||||||||
| Total | ||||||||
The statutory reserve is a gratuity reserve for employees in our subsidiaries in India.
NOTE 12 – COMMITMENTS AND CONTINGENCIES
The Company may be involved in legal proceedings, claims, and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. There are no such matters that are deemed material to the condensed consolidated financial statements as of September 30, 2025, except as disclosed in the legal proceedings section below.
| |
| September 30, 2025, Form 10-Q |
15
Table of Contents
In the U.S., we provide health
insurance, life insurance, and a 401(k) plan wherein the Company matches up to
NOTE 13 – SECURITIES
As of September 30, 2025,
the Company was authorized to issue up to
Our common stock is listed
on the NYSE American (ticker symbol: IGC). This security also trades on the Frankfurt, Stuttgart, and Berlin stock exchanges (ticker
symbol: IGS1). The Company also has
During the six months ended
September 30, 2025, the Company entered into Share Purchase Agreements (the 2025 SPAs) with multiple investors, relating to the sale and
issuance by our company to investors of an aggregate of
NOTE 14 – STOCK-BASED COMPENSATION
As of September 30, 2025,
approximately
Additionally, options held
by advisors and directors to purchase approximately
The above awards include
approximately
| |
| September 30, 2025, Form 10-Q |
16
Table of Contents
The options are valued using a Black-Scholes Pricing Model, and Market-based RSUs are valued based on a lattice model, with the following assumptions:
| Granted in Fiscal 2026 | Granted in Fiscal 2025 | |||||||
| Expected life of options | ||||||||
| Vested options | % | % | ||||||
| Risk-free interest rate | % | % | ||||||
| Expected volatility | % | % | ||||||
| Expected dividend yield | ||||||||
The expense associated with
share-based payments to employees, directors, advisors, and contractors is allocated over the vesting or service period and recognized
in the Selling, general, and administrative expenses (including research and development). For the six months ended September 30, 2025,
the Company’s common stock-based compensation was approximately $
For the six months ended
September 30, 2024, the Company’s common stock-based compensation was approximately $
| Non-vested shares | Shares (in thousands) (#) |
Weighted average grant date fair value ($) |
||||||
| Non-vested shares as of March 31, 2025 | ||||||||
| Granted | ||||||||
| Vested | ( |
) | ||||||
| Cancelled/forfeited | ( |
) | ||||||
| Non-vested shares as of September 30, 2025 | ||||||||
| Options | Shares (in thousands) (#) |
Weighted average grant date fair value ($) |
Weighted average exercise price ($) |
|||||||||
| Options outstanding as of March 31, 2025 | ||||||||||||
| Granted | ||||||||||||
| Vested | ( |
) | ||||||||||
| Cancelled/forfeited | ||||||||||||
| Options outstanding as of September 30, 2025 | ||||||||||||
There was a combined unrecognized
expense of $
NOTE 15 – FAIR VALUE OF FINANCIAL INSTRUMENTS
As of September 30, 2025, the Company’s marketable securities consist of liquid funds, which have been classified as Level 1 of the fair value hierarchy because they have been valued using quoted prices in active markets. The Company’s cash and cash equivalents have also been classified as Level 1 on the same principle. Financial instruments are classified as current if they are expected to be liquidated within the next twelve months. The Company’s remaining investments have been classified as Level 3 instruments as there is little or no market data. Level 3 investments are valued using the cost method.
| |
| September 30, 2025, Form 10-Q |
17
Table of Contents
During the six months ended
September 30, 2025, the Company invested approximately $
The Company does not directly
hold cryptocurrencies, private tokens, or unlisted digital-asset instruments and is therefore not subject to the guidance in ASU 2023-08
(Crypto Assets, ASC 350-60). The investment is liquid, redeemable on a daily basis, and classified as a short-term investment because
it is intended for liquidity management rather than long-term appreciation. As of September 30, 2025, the fair value of the digital assets
through ETP was approximately $
The Company’s marketable-securities portfolio at September 30, 2025, consisted of money-market instruments, certificates of deposit, and the digital assets through ETP, all measured at fair value. The table below summarizes these holdings by fair-value hierarchy (in thousands):
The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of September 30, 2025, and March 31, 2025, and indicates the fair value hierarchy of the valuation techniques the Company used to determine such fair value:
(in thousands)
As of September 30, 2025
| Particular | Adjusted Cost ($) |
Gain ($) |
Loss ($) |
Fair Value ($) |
Cash & Cash Equivalents ($) |
Short Term Investments ($) |
||||||||||||||||||
| Level 1 | ||||||||||||||||||||||||
| Cash | ||||||||||||||||||||||||
| Marketable Debt Funds | ||||||||||||||||||||||||
| Digital Assets | ||||||||||||||||||||||||
| Level 2 | ||||||||||||||||||||||||
| Certificates of Deposit | ||||||||||||||||||||||||
| Level 3 | ||||||||||||||||||||||||
| TOTAL | ||||||||||||||||||||||||
As of March 31, 2025
| Particular | Adjusted Cost ($) |
Gain ($) |
Loss ($) |
Fair Value ($) |
Cash & Cash Equivalents ($) |
Short Term Investments ($) |
||||||||||||||||||
| Level 1 | ||||||||||||||||||||||||
| Cash | ||||||||||||||||||||||||
| Marketable Debt Funds | ||||||||||||||||||||||||
| Marketable Securities | ||||||||||||||||||||||||
| Level 2 | ||||||||||||||||||||||||
| Certificates of Deposit | ||||||||||||||||||||||||
| Level 3 | ||||||||||||||||||||||||
| TOTAL | ||||||||||||||||||||||||
NOTE 16 – SEGMENT INFORMATION
FASB ASC 280, “Segment Reporting,” establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available and is evaluated regularly by the chief operating decision maker, or decision making group (CODM), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. The Company’s CODM is the Company’s Chief Executive Officer (CEO). The CEO reviews financial information presented on an operating segment basis for the purposes of making operating decisions and assessing financial performance. As of the date of this report and in preparation for the new and different source of revenue, the Company has determined that it operates in a operating and reportable segment, Life Sciences segment.
|
September 30, 2025, Form 10-Q |
18
Table of Contents
The following provides information required by ASC 280-10-50-38 “Entity-wide Information”:
| (in thousands) | ||||||||||||||||
| Three months ended September 30, 2025 ($) |
Three months ended September 30, 2024 ($) |
Six months ended September 30, 2025 ($) |
Six months ended September 30, 2024 ($) |
|||||||||||||
| Life Sciences segment | ||||||||||||||||
| Wellness and lifestyle | ||||||||||||||||
| White labeling services | ||||||||||||||||
| Total | ||||||||||||||||
For information on revenue by product and service, refer to Note 2, “Summary of Significant Accounting Policies”.
| (in thousands) | ||||||||||
| Segments | Country | Three months ended September 30, 2025 ($) |
Six months ended September 30, 2025 ($) |
|||||||
| America | U.S. | |||||||||
| Colombia | ||||||||||
| Total | ||||||||||
| (in thousands) | ||||||||||
| Segments | Country | Three months ended September 30, 2024 ($) |
Six months ended September 30, 2024 ($) |
|||||||
| America | U.S. | |||||||||
| Colombia | ||||||||||
| Total | ||||||||||
| |
| September 30, 2025, Form 10-Q |
19
Table of Contents
| (in thousands) | ||||||||||||
| Nature of assets | USA (Country of Domicile) ($) |
Foreign Countries (India and Colombia) ($) |
Total as of September 30, 2025 ($) |
|||||||||
| Intangible assets, net | ||||||||||||
| Property, plant, and equipment, net | ||||||||||||
| Claims and advances | ||||||||||||
| Operating lease asset | ||||||||||||
| Total non-current assets | ||||||||||||
| (in thousands) | ||||||||||||
| Nature of assets | USA (Country of Domicile) ($) |
Foreign Countries (India and Colombia) ($) |
Total as of March 31, 2025 ($) |
|||||||||
| Intangible assets, net | ||||||||||||
| Property, plant, and equipment, net | ||||||||||||
| Claims and advances | ||||||||||||
| Operating lease asset | ||||||||||||
| Total non-current assets | ||||||||||||
NOTE 17 – SUBSEQUENT EVENTS
| 1) | On October 10, 2025, subsequent to the balance sheet date, Stockholders approved, and the Company filed with the Maryland State Department of Assessments & Taxation the required articles of amendment to its articles of incorporation increasing the authorized common shares from |
| |
| September 30, 2025, Form 10-Q |
20
Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The purpose of this Management’s Discussion and Analysis (MD&A) is to provide an understanding of IGC Pharma, Inc.’s (“IGC,” “IGC Pharma,” the “Company,” “we,” “our,” and/or “us”) consolidated financial condition and results of operations and cash flows. The MD&A should be read in conjunction with our unaudited condensed financial statements and related notes that appear elsewhere in this Quarterly Report on Form 10-Q for the six months ended September 30, 2025, and the Annual Report on Form 10-K for the fiscal year ended March 31, 2025, filed with the SEC on June 27, 2025 (the 2025 Form 10-K). The Company’s actual results could differ materially from those discussed here. Factors that could cause differences include those discussed in the “Forward-Looking Statements” and “Risk Factors” sections and discussed elsewhere in this report. The risks and uncertainties can cause actual results to differ significantly from those in our forward-looking statements or implied in historical results and trends. Accordingly, we caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as expressly required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those outlined in the forward-looking statements.
Overview
IGC Pharma Inc. is a clinical-stage pharmaceutical company attempting to utilize Artificial Intelligence (AI) technologies to develop innovative therapies for Alzheimer’s Disease (AD), related neurodegenerative disorders, and metabolic conditions. The Company’s lead therapeutic candidate, IGC-AD1, is currently in Phase 2 clinical development targeting agitation in Alzheimer’s dementia—a prevalent and debilitating behavioral symptom. During the quarter ended September 30, 2025, IGC Pharma successfully enrolled more than 50% of patients in the ongoing clinical trial, representing a key operational milestone and reflecting continued progress toward study completion and potential regulatory advancement.
In parallel, IGC Pharma is accelerating the integration of its proprietary AI platform in an effort to enhance drug discovery, optimize clinical trial design, and identify novel therapeutic targets. The Company’s AI models attempt to leverage multimodal data—from clinical biomarkers to behavioral patterns—to predict treatment response, enable early disease detection, and support the creation of precision-based therapies in Alzheimer’s and other neurological diseases, although there can be no assurance thereof. We believe this AI-driven infrastructure not only strengthens internal research productivity but also positions IGC Pharma as an emerging player in the convergence of pharmaceuticals and intelligent data science, although there can be no assurance thereof.
Life Sciences Segment
IGC Pharma, a clinical-stage company developing treatments for Alzheimer’s disease, is committed to transforming patient care by striving to offer faster acting and more effective solutions. Our lead drug, IGC-AD1, embodies this vision by tackling a critical challenge – managing agitation in Alzheimer’s dementia. Early results from our Phase 2 trial are promising: IGC-AD1 effectively reduced agitation in patients compared to a placebo, and crucially, it did so faster than traditional medications. While existing anti-psychotics can take as long 6 to 12 weeks to show effects, we believe IGC-AD1 has the potential to act within two weeks. This potentially faster onset of action could significantly improve patient care and represents a potential breakthrough in managing Alzheimer’s-related
agitation, although there can be no assurance thereof. In addition, we have created in-house wellness brands, available through online channels that are compliant with relevant federal, state, and local laws and regulations. We derive revenue from our in-house wellness non-pharmaceutical formulations that are sold over-the-counter (OTC).
MINT-AD
Currently, we are working on developing a Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD). This tool aims to support clinicians in real-world decision-making towards reducing Alzheimer’s false negatives and delayed diagnosis. We are developing MINT-AD for three aims/phases: risk stratification for AD, cognitive decline prediction 2-5 years in advance, and deployment as a physician’s tool.
According to the World Alzheimer Report, more than 400 million people globally may carry Alzheimer’s-related pathology before any clinical symptoms appear. Yet primary care physicians, particularly those outside urban centers, often lack the tools needed to detect early cognitive risk. This diagnostic gap leads to missed or delayed diagnoses, limiting timely intervention, reducing eligibility for clinical trials, and ultimately worsening patient outcomes. MINT-AD aims to bridge this gap by extending cognitive diagnostics beyond neurology clinics, expensive PET scans, and other tests, to general practices, rural areas, and underserved populations.
| |
| September 30, 2025, Form 10-Q |
21
Table of Contents
MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories. The platform is being designed for integration into physician workflows to help improve early detection, care personalization, and clinical trial enrolment.
Our Business Strategy
The business strategy includes:
| ● | Completing the Phase 2/3 CALMA trail. | |
| ● | Completing MINT-AD. | |
| ● | Advancing tox studies to enable disease modifying trials with IGC-AD1. | |
| ● | Applying for non-dilutive grants. | |
| ● | Advancing TGR-63 as a potential therapeutic for AD. | |
| ● | Strengthening clinical credibility and visibility. |
We believe developing a drug for both symptom and disease-modifying agents has less risk due to the need for expensive multi-year trials. However, there is considerable upside and significant value creation to the extent we obtain a first-in-class advantage, of which there can be no assurance. If we were to obtain a first-in-class advantage, such an advantage could result in significant growth if and when an approved drug such as IGC-AD1 launches.
We believe that additional investment in clinical trials, AI, R&D, facilities, marketing, advertising, and the acquisition of complementary products and businesses will be critical to the ongoing growth of the Life Sciences segment. Although there can be no assurance, we believe these investments will fuel the development and delivery of innovative products that drive positive patient and customer experiences. We hope to leverage our R&D and intellectual property to develop ground-breaking, science-based products that are proven effective through clinical trials, subject to FDA approval. Although there can be no assurance, we believe this strategy can improve our existing products and lead to the creation of new products that can provide treatment options for multiple conditions, symptoms, and side effects. Management is committed to its core short-term goals, completion of the Phase 2 trial on IGC-AD1, and deploying MINT-AD.
Company Highlights for the Quarter ended September 30, 2025
| ● | On September 22, 2025, the Company reached a key enrollment milestone of more than 50% for its ongoing Phase 2 CALMA clinical trial evaluating IGC AD-1 for the treatment of agitation in Alzheimer’s disease. | |
| ● | On September 9, 2025, the Company announced that its Artificial Intelligence (AI) team been recognized with a special award for excellence in clean code development as part of the National Institute on Aging (NIA) PREPARE Challenge. | |
| ● | On September 2, 2025, the Company announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC AD-1, a novel investigational treatment for agitation in Alzheimer’s dementia, to a new international site at Island Health’s Royal Jubilee Hospital in Victoria, British Columbia, Canada. | |
| ● | On August 28, 2025, the Company announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application US 17/613,909. The patent application, IGC510, is for a proprietary method for treating individuals suffering from stammering, stuttering, or Tourette’s syndrome with THC and/or CBD. | |
| ● | On August 25, 2025, the Company announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational drug candidate for treating agitation in patients with Alzheimer’s disease. The Company has added a clinical site at the Lynn Health Science Institute (LHSI) in Oklahoma City, Oklahoma. | |
| ● | On August 12, 2025, the Company announced promising preclinical results for IGC-M3, a novel small molecule designed to address multiple biological drivers of Alzheimer’s disease. IGC-M3 demonstrated activity in laboratory models against beta-amyloid aggregation, oxidative stress, mitochondrial dysfunction, and neuroinflammation, four key contributors to Alzheimer’s pathology. | |
| ● | On August 5, 2025, the Company announced encouraging preclinical data on its investigational molecule “IGC-M3”. The invitro results demonstrates that IGC-M3 may offer disease-modifying potential by targeting multiple biological mechanisms central to Alzheimer’s pathology, including amyloid aggregation, oxidative stress, mitochondrial dysfunction, and neuroinflammation. | |
| ● | On July 21, 2025, the Company announced that its Principal Scientist, Jagadeesh Rao, Ph.D., has been awarded the Best Researcher Award at the 11th Annual World Neuroscientist Awards. | |
| ● | On July 10, 2025, the Company announced the development of MINT-AD, Multimodal Interpretable Transformer for Alzheimer’s, the Company’s proprietary AI-powered diagnostic platform designed to identify individuals at high risk of cognitive decline years before symptoms appear. |
| |
| September 30, 2025, Form 10-Q |
22
Table of Contents
Results of Operations for the Three Months Ended September 30, 2025, and September 30, 2024
The historical results presented below are not necessarily indicative of the results that may be expected for any future period. The following table presents an overview of our results of operations for the three months ended September 30, 2025, and September 30, 2024:
Statement of Operations (in thousands, unaudited)
| Three months ended September 30, | ||||||||||||||||
| 2025 ($) | 2024 ($) | Change ($) | Percent Change | |||||||||||||
| Revenue | 191 | 412 | (221 | ) | 54 | % | ||||||||||
| Cost of revenue | (92 | ) | (214 | ) | 122 | 57 | % | |||||||||
| Gross profit | 99 | 198 | (99 | ) | 50 | % | ||||||||||
| Selling, general, and administrative expenses | (1,410 | ) | (1,041 | ) | (369 | ) | 35 | % | ||||||||
| Research and development expenses | (1,588 | ) | (917 | ) | (671 | ) | 73 | % | ||||||||
| Operating loss | (2,899 | ) | (1,760 | ) | (1,139 | ) | 65 | % | ||||||||
| Other income, net | 1,078 | 43 | 1,035 | 2,407 | % | |||||||||||
| Loss before income taxes | (1,821 | ) | (1,717 | ) | (104 | ) | 6 | % | ||||||||
| Income tax expense/benefit | - | - | - | - | ||||||||||||
| Net loss | (1,821 | ) | (1,717 | ) | (104 | ) | 6 | % | ||||||||
Revenue – Revenue was approximately $191 thousand and $412 thousand for the three months ended September 30, 2025, and September 30, 2024, respectively. Revenue in both quarters was primarily derived from our Life Sciences segment, which involved providing white-label manufactured products and sales of in-house products, among others. There is a decrease in revenue as our core focus is on advancing IGC-AD1, completing the Phase 2 trial, and developing MINT-AD for the early diagnosis of Alzheimer’s disease. In addition, there was a planned transition period associated with the disposition of the Company’s Vancouver manufacturing facility pursuant to the Favorable Contract between the Company and the Buyer. During this period, production and fulfillment activities were reduced as operations were transferred to the Buyer under the Favorable Contract. For more information, please refer to Note 7 – “Disposition of Assets”.
Cost of revenue – Cost of revenue amounted to approximately $92 thousand for the three months ended September 30, 2025, compared to $214 thousand in the three months ended September 30, 2024, this represents gross margins of 52% and 48%, respectively. The cost of revenue is primarily attributable to the cost of raw materials, labor, and other direct overheads required to produce our products in the Life Science segment. Typically, the gross margin in the Life Sciences business will fluctuate from one quarter to another based on the mix within the Life Sciences business between white label, private label, and branded products. There is insufficient revenue to model or project gross margins.
Selling, general and administrative expenses (“SG&A”)– SG&A expenses primarily encompass various costs such as employee-related expenses, sales commissions, professional fees, legal fees, marketing expenses, other corporate expenses, allocated general overhead, provisions, depreciation, and write-offs related to doubtful accounts and advances. During the three months that ended September 30, 2025, SG&A expenses increased by approximately $369 thousand or 35% to approximately $1.4 million during the three months ended September 30, 2024. The increase of $369 thousand is attributed to an increase in the marketing and corporate expenses, as well as non-cash expenses of approximately $250 thousand and a one-time expense of approximately $50 thousand.
Research and development expenses (“R&D”)– R&D expenses were attributed to our Life Sciences segment. The R&D expenses increased by approximately $671 thousand or 73% to approximately $1.6 million during the three months ended September 30, 2025, from approximately $917 thousand. It is primarily attributable to the progression of Phase 2 trials on IGC-AD1 and pre-clinical studies on the other small molecule assets. We anticipate increased R&D expenses as the development of our other small molecule assets targeting Alzheimer’s and the Phase 2 trial on Alzheimer’s expand.
Other income, net – Other net income increased by approximately $1 million or 2,407% during the thousand months ended September 30, 2025. As a result, the total other income for the three months ended September 30, 2025, and 2024, is approximately $1.2 million and $43 thousand, respectively. Other income includes interest and rental income, dividend income, profit from the sale of assets, unrealized gains from investments, net income, and income from scrap sales. Increase in other income is attributed to profit from the disposition of assets, please refer to Note -7 “Disposition of Assets”.
| |
| September 30, 2025, Form 10-Q |
23
Table of Contents
Results of Operations for the Six Months Ended September 30, 2025, and September 30, 2024
The historical results presented below are not necessarily indicative of the results that may be expected for any future period. The following table presents an overview of our results of operations for the six months ended September 30, 2025, and September 30, 2024:
Statement of Operations (in thousands, unaudited)
| Six months ended September 30, | ||||||||||||||||
| 2025($) | 2024($) | Change ($) | Percent Change | |||||||||||||
| Revenue | 519 | 684 | (165 | ) | 24 | % | ||||||||||
| Cost of revenue | (266 | ) | (323 | ) | 57 | 18 | % | |||||||||
| Gross profit | 253 | 361 | (108 | ) | 30 | % | ||||||||||
| Selling, general, and administrative expenses | (2,618 | ) | (2,711 | ) | 93 | 3 | % | |||||||||
| Research and development expenses | (2,439 | ) | (1,806 | ) | (633 | ) | 35 | % | ||||||||
| Operating loss | (4,804 | ) | (4,156 | ) | (648 | ) | 16 | % | ||||||||
| Other income, net | 1,384 | 61 | 1,323 | 2,169 | % | |||||||||||
| Loss before income taxes | (3,420 | ) | (4,095 | ) | 675 | 16 | % | |||||||||
| Income tax expense/benefit | - | - | - | - | ||||||||||||
| Net loss | (3,420 | ) | (4,095 | ) | 675 | 16 | % | |||||||||
Revenue – Revenue was approximately $519 thousand and $684 thousand for the six months ended September 30, 2025, and September 30, 2024, respectively. Revenue in both quarters was primarily derived from our Life Sciences segment, which involved providing white-label manufactured products and sales of holistic health care products, among others. There is a decrease in revenue as our core focus is on advancing IGC-AD1, completing the Phase 2 trial, and developing MINT-AD for the early diagnosis of Alzheimer’s disease. In addition, there was a planned transition period associated with the disposition of the Company’s Vancouver manufacturing facility pursuant to the Favorable Contract. During this period, production and fulfillment activities were reduced as operations were transferred to the Buyer under the Favorable Contract. For more information, please refer to Note 7 – “Disposition of Assets”.
Cost of revenue – Cost of revenue amounted to approximately $266 thousand for the six months ended September 30, 2025, compared to $323 thousand in the six months ended September 30, 2024, this represents gross margins of 49% and 53%, respectively. The cost of revenue is primarily attributable to the cost of raw materials, labor, and other direct overheads required to produce our products in the Life Science segment. Typically, the gross margin in the Life Sciences business will fluctuate from one quarter to another based on the mix within the Life Science business between white label, private label, and branded products. There is insufficient revenue to model or project gross margins.
SG&A– SG&A expenses primarily encompass various costs such as employee-related expenses, sales commissions, professional fees, legal fees, marketing expenses, other corporate expenses, allocated general overhead, provisions, depreciation, and write-offs related to doubtful accounts and advances. During the six months ended September 30, 2025, SG&A expenses decreased by approximately $93 thousand or 3% to approximately $2.6 million during the six months ended September 30, 2025, from approximately $2.7 million. This decline in SG&A expenses is attributable to the Company’s focused efforts to optimize corporate-level operational efficiency by lowering employee–related costs through headcount alignment and compensation restructuring, and reducing spending on legal and professional services through more efficient vendor management. These optimizations allowed the Company to preserve capital and extend its operational runway while maintaining the infrastructure necessary to support clinical development and strategic initiatives..
R&D– R&D expenses were attributed to our Life Sciences segment. The R&D expenses increased by approximately $633 thousand or 35% to approximately $2.4 million during the six months ended September 30, 2025, from approximately $1.8 million. It is primarily attributable to the progression of Phase 2 trials on IGC-AD1 and pre-clinical studies on the other small molecule assets. We anticipate increased R&D expenses as the development of our other small molecule assets targeting Alzheimer’s and the Phase 2 trial on Alzheimer’s expand.
Other income, net – Other net income increased by approximately $1.3 million or 2,170% during the six months ended September 30, 2025. As a result, the total other income for the six months ended September 30, 2025, and 2024 is approximately $1.4 million and $61 thousand, respectively. Other income includes interest and rental income, dividend income, profit from the sale of assets, unrealized gains from investments, net income, and income from scrap sales. Increase in other income is attributed to tax credit of approximately $263 thousand and profit from the disposition of assets, please refer to Note -7 “Disposition of Assets”.
| |
| September 30, 2025, Form 10-Q |
24
Table of Contents
Liquidity and Capital Resources
Our sources of liquidity are cash and cash equivalents, funds raised through the ATM offering, cash flows from operations, short-term and long-term borrowings, and short-term liquidity arrangements. The Company continues to evaluate various financing sources and options to raise working capital to help fund current research and development programs and operations. The Company does not have any material long-term debt, capital lease obligations, or other long-term liabilities except as disclosed in this report. Please refer to Note 12, “Commitments and Contingencies,” and Note 11, “Loans and Other Liabilities,” in Item 1 of this report for further information on the Company’s commitments and contractual obligations.
On June 24, 2025, the Company entered into an amendment to extend the Credit Agreement. The amendment extends the term of the Credit Agreement, which was set to expire, under the same terms and conditions as previously disclosed, with the exception of i) a reduction in the facility fees from $84,000 to $48,000 and ii) interest, calculated according to the interest rate mentioned in the Certificate of Deposit, as the case may be, plus an applicable margin of 1.2%, instead of 1%. All other material terms of the Credit Agreement remain unchanged.
In the first quarter of Fiscal 2026, the Company entered into the 2025 Share Purchase Agreements (2025 SPAs) with multiple investors, relating to the sale and issuance by our company to the investors of an aggregate of 2,803,333 shares of our common stock, for a total purchase price of $841,000, or $0.30 per share, subject to the terms and conditions set forth in the 2025 SPAs. The investments are subject to customary closing conditions, including NYSE approval.
On September 29, 2025, the Company entered into the Sale Agreement, pursuant to which the Company sold assets associated with its Vancouver, Washington facility for approximately $2.7 million, subject to the satisfaction of certain closing conditions. The facility had previously generated an annual net cash outflow of approximately $600 thousand from fixed overhead and non-core manufacturing operations. The sale eliminates the recurring cash loss while preserving preferential supply rights that allow the Company to continue sourcing formulations at competitive pricing from 2027 onward. The Company also retains a contingent 10% interest in any future sale of the business by the Buyer. Please refer to Note 7 – “Disposition of Assets” and Item 5 – “Other Information”.
As part of its treasury management program, the Company invested approximately $25 thousand in a U.S.-listed digital asset through an ETP during the three-month quarter ended September 30, 2025. The investment is classified as a short-term marketable security, and is marked to market each period. The Company does not directly hold cryptocurrencies or other digital tokens.
The equity and the credit facility serve to minimize ongoing liquidity requirements and ensure the Company’s ability to sustain its operations. Furthermore, the Company intends to raise additional funds through private placement and ATM offerings, subject to market conditions, although there can be no assurance that such financing efforts will be successful. The Company expects to raise further capital for its research and development initiatives as and when it is able to do so, in an ATM offering or private placement. In addition, there can be no assurance of the terms thereof, and any subsequent equity financing sought may have dilutive effects on our current shareholders. While there is no guarantee that we will be successful, we are applying to non-dilutive funding opportunities such as Small Business Research and Development programs. In addition, subject to limitations on the amount of capital that can be raised, the Company expects to utilize its shelf registration on a statement on Form S-3 to raise capital through at-the-market offerings or otherwise. Please refer to Note 13 – “Securities”, for more information.
| |
| September 30, 2025, Form 10-Q |
25
Table of Contents
| (in thousands, unaudited) | ||||||||||||||||
| As of September 30, 2025 ($) |
As of March 31, 2025 ($) |
Change | Percent Change |
|||||||||||||
| Cash and cash equivalents | 1,105 | 405 | 700 | 173 | % | |||||||||||
| Working capital | 490 | 639 | (149 | ) | (23 | )% | ||||||||||
Cash and cash equivalents
Cash and cash equivalents increased by approximately $700 thousand to $1.1 million in the six months ended September 30, 2025, from $405 thousand as of March 31, 2025, an increase of approximately 173%.
Summary of Cash flows
| (in thousands, unaudited) | ||||||||||||||||
Six
months ended | Percent | |||||||||||||||
| 2025 | 2024 | Change | Change | |||||||||||||
| Cash used in operating activities | (3,497 | ) | (2,748 | ) | (749 | ) | 27 | % | ||||||||
| Cash (used in) provided by investing activities | 206 | (196 | ) | 402 | 205 | % | ||||||||||
| Cash provided by financing activities | 3,961 | 3,301 | 660 | 20 | % | |||||||||||
| Effects of exchange rate changes on cash and cash equivalents | 30 | (9 | ) | 39 | 100 | % | ||||||||||
| Net increase (decrease) in cash and cash equivalents | 700 | 348 | 352 | 101 | % | |||||||||||
| Cash and cash equivalents at the beginning of period | 405 | 1,198 | (793 | ) | 66 | % | ||||||||||
| Cash and cash equivalents at the end of the period | 1,105 | 1,546 | (441 | ) | (29 | )% | ||||||||||
Operating Activities
Net cash used in operating activities for the six months ended September 30, 2025, was approximately $3.5 million. It consists of a net loss of approximately $3.4 million, a positive impact on cash due to non-cash expenses of approximately $363 thousand, and a negative change in operating assets and liabilities of approximately $441 thousand. Non-cash expenses consist of an amortization and depreciation charge of approximately $260 thousand, stock-based expenses of approximately $1.2 million, and profit on sale of fixed assets of approximately $1.1 million. In addition, changes in operating assets and liabilities had a negative impact of approximately $441 thousand on cash, of which a net positive impact of approximately $220 thousand is due to an increase in deposits and advances, and a negative impact of approximately $506 thousand is due to an increase in accrued and other liabilities, a net negative impact of approximately $253 thousand is due to an increase in accounts payable, a net positive impact of approximately $85 thousand is due to an increase in operating lease assets, and net other current assets and liabilities of approximately $13 thousand.
Net cash used in operating activities for the six months ended September 30, 2024, was approximately $2.7 million. It consists of a net loss of approximately $4.1 million, a positive impact on cash due to non-cash expenses of approximately $1.1 million, and a positive change in operating assets and liabilities of approximately $249 thousand. Non-cash expenses consist of an amortization and depreciation charge of approximately $307 thousand and stock-based expenses of approximately $804 thousand. In addition, changes in operating assets and liabilities had a positive impact of approximately $249 thousand on cash, of which a net negative impact of approximately $227 thousand is due to an increase in deposits and advances, and a positive impact of approximately $467 thousand is due to increase in accrued and other liabilities, a net negative impact of approximately $5 thousand is due to an increase in accounts payable and net other current assets and liabilities of approximately $14 thousand.
| |
| September 30, 2025, Form 10-Q |
26
Table of Contents
Investing Activities
Net cash used in investing activities for the six months ended September 30, 2025, was approximately $206 thousand, which is comprised of expenses of approximately $411 thousand for the acquisition and development of intangible assets, approximately $25 thousand for the investment in short term investment, and approximately $642 thousand for the net purchase of property, plant, and equipment.
Net cash used in investing activities for the six months ended September 30, 2024, was approximately $196 thousand, which is comprised of expenses of approximately $145 thousand for the acquisition, and development of intangible assets, and approximately $51 thousand for the net purchase of property, plant, and equipment.
Financing Activities
Net cash provided by financing activities was approximately $3.9 million for the six months ended September 30, 2025, which is comprised of net proceeds from issuance of equity stock of approximately $3.9 million, and re-payment of the loan of approximately $2 thousand. Please refer to Note 13 – “Securities”, for more information.
Net cash provided by financing activities was approximately $3.3 million for the six months ended September 30, 2024, which is comprised of net proceeds from issuance of equity stock of approximately $3.3 million, and re-payment of the loan of approximately $2 thousand. Please refer to Note 13 – “Securities”, for more information.
Treasury Strategy and Capital Allocation Considerations
Management continually evaluates opportunities to optimize the Company’s capital structure and enhance stockholders’ equity while maintaining adequate liquidity to support operations. Since early 2024, we have assessed the potential use of digital assets, including digital assets and other cryptocurrencies, as part of our treasury management strategy. We believe that allocating a portion of our cash reserves to digital assets could diversify our treasury holdings, potentially enhance our balance sheet if the assets appreciate, and align with emerging best practices of certain public companies.
We began implementing this policy during the quarter ending September 30, 2025. The timing, size, and type of investments will be based on prevailing market conditions, liquidity needs, and risk management considerations. These investments involve material risks, as discussed in Item 1A – “Risk Factors”.
Off-Balance Sheet Arrangements
We do not have any outstanding derivative financial instruments, off-balance sheet guarantees, interest rate swap transactions, or foreign currency forward contracts. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity, or market risk support to such entity. We do not have any variable interest in an unconsolidated entity that provides financing, liquidity, market risk, or credit support to us or that engages in leasing, hedging, or research and development services with us.
Critical Accounting Policies
While all accounting policies impact financial statements, certain policies may be viewed as critical. Critical accounting policies are those that are both most important to the portrayal of financial condition and results of operations and that require management’s most subjective or complex judgments and estimates. Our management believes that the following policy that falls within this category in addition to the policies on revenue recognition, inventory, accounts receivable, foreign currency translation, impairment of long-lived assets and investments, stock-based compensation, and cybersecurity:
| |
| September 30, 2025, Form 10-Q |
27
Table of Contents
Digital Asset Investments
During the six months ended September 30, 2025, the Company invested approximately $25 thousand in a U.S.-listed digital asset through ETPs. The investment is classified as a short-term marketable security and is marked to market each period. The Company does not directly hold cryptocurrencies or other digital tokens. Holdings in ETPs will be accounted for as equity securities under ASC 321, Investments – Equity Securities, and measured at fair value with changes recognized in earnings. Fair value will be determined using quoted prices in active markets (Level 1 inputs).
For direct holdings of digital assets, the Company will present in the notes a roll-forward of activity, including the opening balance, additions, dispositions, gains and losses recognized during the period, and the ending balance, as well as any significant concentrations and restrictions.
Please see our disclosures in Note 2 – Summary of Significant Accounting Policies to the Notes to the Unaudited Condensed Consolidated Financial Statements in this report, in the Notes to the Audited Consolidated Financial Statements in the 2025 Form 10-K, as well as Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations in the 2025 Form 10-K, for a discussion of all our critical and significant accounting policies.
Recent Accounting Pronouncements
Changes to U.S. GAAP are established by the Financial Accounting Standards Board FASB) in the form of accounting standards updates (ASUs) to the FASB’s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. Newly issued ASUs not listed are expected to have no impact on the Company’s consolidated financial position and results of operations because either the ASU is not applicable, or the impact is expected to be immaterial. Recent accounting pronouncements that may apply to us are described in Note 2, “Significant Accounting Policies” to the Notes to the Unaudited Condensed Consolidated Financial Statements in this report and in the Notes to the Audited Consolidated Financial Statements in Part II of our 2025 Form 10-K.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Item 3 does not apply to us because we are a smaller reporting company.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our Management maintains disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”) that are designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Exchange Act is processed, recorded, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to Management, including our Chief Executive Officer (our principal executive officer) and Principal Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.
Our Management, including the Chief Executive Officer and Principal Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective in ensuring that the information required to be disclosed in the reports filed or submitted by us under the Exchange Act was recorded, processed, summarized and reported within the requisite time periods specified in SEC rules and forms and that such information was accumulated and communicated to our Management, including our Chief Executive Officer and Principal Financial Officer, as appropriate to allow for timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
Our Management, including our Chief Executive Officer and Principal Financial Officer, evaluated our “internal control over financial reporting” as defined in Exchange Act Rule 13a-15(f) to determine whether any changes in our internal control over financial reporting occurred during the three months ended September 30, 2025, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Based on that evaluation, there were no changes in our internal control over financial reporting during the three months ended September 30, 2025, that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.
| |
| September 30, 2025, Form 10-Q |
28
Table of Contents
PART II – OTHER INFORMATION
Item 1. Legal Proceedings
The Company may be involved in legal proceedings, claims, and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. As of September 30, 2025, we were not party to any material legal proceedings other than those disclosed below.
During the quarter ended September 30, 2025, the following material litigation is pending:
Engineering and Consulting Group SAS et al. v IGC Pharma Inc., case file no. 110016000050202247710 (Prosecutor’s Office 393 Sectional Economic Crimes Unit, Bogota, Colombia). The Company and the ECG corporation are in a contractual dispute. The Company filed a complaint against four (4) individuals with the Prosecutor’s Office 393 Sectional Economic Crimes Unit, Bogota, Colombia, under file no. 110016000050202247710 for charges of fraud, falsification of a private document, and conspiracy to commit a crime. The complaint was filed in 2022. In December 2023, the case was reviewed by the investigator and scheduled and accepted for a hearing by the prosecutor in calendar 2024. During the three months ended September 30, 2025, there were no material changes.
Item 1A. Risk Factors
Following are the material changes to the risk factors disclosed in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended March 31, 2025, filed with the SEC on June 27, 2025.
Investment in Digital Assets Could Adversely Affect Our Financial Condition and Results of Operations
Management is considering a treasury policy that permits the investment of a limited portion of our available funds in digital assets, such as digital assets and other cryptocurrencies, either directly or through exchange-traded products (ETPs) that hold such assets. We have not made any purchases as of the filing date of this Quarterly Report. Investments in digital assets are subject to significant risks and volatility:
| ● | Price Volatility: The market prices of digital assets, and other cryptocurrencies have historically been highly volatile and may be influenced by factors beyond our control, including market sentiment, macroeconomic conditions, changes in supply and demand, geopolitical events, regulatory developments, technological changes, and market disruptions. Large fluctuations in fair value could materially affect our reported earnings, financial position, and stock price. | |
| ● | Regulatory Risk: Digital assets are a relatively new asset class and are subject to evolving U.S. federal, state, and foreign laws and regulations. Regulatory changes, or the interpretation or enforcement of existing laws, could restrict our ability to buy, sell, hold, or transact in digital assets and could adversely impact their value. |
| |
| September 30, 2025, Form 10-Q |
29
Table of Contents
| ● | Custody and Operational Risk: If we invest directly in digital assets, we will be exposed to operational and custody risks, including loss or theft of private keys, cybersecurity breaches, fraud, and insolvency of custodians. If we invest via ETPs, we will be subject to risks specific to those funds, including tracking errors relative to the underlying asset, reliance on the sponsor and custodian, and management fees. | |
| ● | Liquidity Risk: The trading venues for digital assets and related products may experience outages, disruptions, or other operational issues that can impair our ability to transact, especially during times of market stress. | |
| ● | Tax and Accounting Impact: Changes in U.S. tax law, including the Corporate Alternative Minimum Tax (CAMT), could cause us to incur tax liabilities on unrealized gains in digital assets. Accounting standards require us to record changes in fair value through earnings each reporting period, which may increase our earnings volatility. |
There is no assurance that any investment in digital assets will result in a positive return, and we may incur losses that could adversely affect our business, financial condition, and results of operations.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5.
On October 10, 2025, the shareholders of IGC Pharma Inc. approved an amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of common stock from 150,000,000 to 600,000,000. Following shareholder approval, the amendment was filed with the State Department of Assessments and Taxation of Maryland. As of the date of this report, the increase in authorized capital is pending final effectiveness.
The Company will update stockholders regarding the final approval and effectiveness of the authorized capital increase in subsequent filings as appropriate.
| |
| September 30, 2025, Form 10-Q |
30
Table of Contents
Item 6. Exhibits
| Exhibit | ||
| Number | Exhibit Description | |
| 3.1 | Amended and Restated Articles of Incorporation of the Registrant, as amended on August 1, 2012 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on August 6, 2012). | |
| 3.2 | Articles of Amendment to the Company’s Amended and Restated Articles of Incorporation filed with the State Department of Assessments and Taxation of Maryland on March 7, 2023 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on March 21, 2023). | |
| 3.3 | By-laws of the Registrant (incorporated by reference to Exhibit 3.2 to the Company’s Post-Effective Amendment No.1 to Form S-3 filed on January 22, 2021). | |
| 3.4 | Amendment to the Amended and Restated Articles of Incorporation of the Registrant as amended on August 2, 2014 (incorporated by reference to Exhibit 3.3 to the Company’s Post-Effective Amendment No.1 to Form S-3 filed on January 22, 2021). | |
| 3.5 | Amendment to the Bylaws of the Company dated March 2, 2023 (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on March 21, 2023). | |
| 10.1 | Sale of Assets and Manufacturing Agreement between Holi Hemp LLC, dba HH Processors, and Wellness Essentials Northwest Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on November 14, 2025). | |
| 31.1* | Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer. | |
| 31.2* | Rule 13a-14(a) / 15d-14(a) Certification of Principal Financial Officer. | |
| 32.1** | Certifications pursuant to 18 U.S.C. §1350. | |
| 101.INS* | Inline XBRL Instance Document. | |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document. | |
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document. | |
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |
| 104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
| * | Filed herewith. |
| ** | Furnished herewith. |
| † | Certain schedules or similar attachments to this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K. |
| |
| September 30, 2025, Form 10-Q |
31
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| IGC PHARMA, INC. | ||
| Date: November 14, 2025 | By: | /s/ Ram Mukunda |
| Ram Mukunda | ||
President and Chief Executive Officer (Principal Executive Officer) | ||
| Date: November 14, 2025 | By: | /s/ Claudia Grimaldi |
| Claudia Grimaldi | ||
Vice-president & Chief Compliance Officer (Principal Financial Officer) | ||
| |
| September 30, 2025, Form 10-Q |
32
